QUALITY MANAGEMENT SERVICES
BioBoston CRO provides clinical trial quality management services for sponsors that need a practical framework for quality planning, risk-based quality management, quality signals, governance, issue escalation, and continuous control across a study or clinical program. Support may include a clinical quality plan, risk assessment, quality-tolerance or signal framework, dashboard, governance model, or remediation of a fragmented quality process.
Global Reach
Therapeutic Area Coverage
Years of Experience
START A CONVERSATION
Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
The engagement should be scoped around the current state of the work, the intended decision or milestone, the source package, and the sponsor's approval responsibilities.
Create a study or program quality plan that connects critical-to-quality factors, risks, controls, signals, review cadence, decisions, and escalation.
Translate protocol and operational risks into defined indicators, thresholds, data sources, owners, actions, and periodic review.
Integrate oversight, audits, deviations, CAPAs, monitoring signals, data trends, safety concerns, vendor issues, and governance decisions into one control model.
when needed
Problems
The service is most valuable when the team can identify the specific control gap, decision, deliverable, or
recovery need rather than requesting generic capacity.
Scope
The exact scope depends on the maturity of the work, the quality of the inputs, the sponsor’s procedures,
the review model, and the target milestone.
Deliverables
Deliverables should be confirmed at kickoff and linked to defined sponsor decisions, review cycles, and downstream handoffs.
Client inputs
The sponsor does not need every detail finalized before kickoff, but approved decisions, open questions, source owners, reviewers, and deadlines must be distinguishable.
Process
1. Confirm the purpose, current state, intended use, milestone, stakeholders, responsibilities, systems or vendors, and agreed deliverables.
2. Review available source materials, prior decisions, procedures, evidence, and open issues; issue a focused gap and dependency list.
3. Develop the work plan, specifications, document, assessment, or control package included in scope.
4. Coordinate review through named sponsor and cross-functional decision owners and maintain a controlled open-item and comment process.
5. Perform the agreed technical, quality, consistency, or operational checks and document remaining risks or limitations.
6. Prepare the approved handoff, implementation, submission, remediation, archive, or next-step package as defined in scope.
Considerations
The work should remain proportionate to the risk and intended use, follow the sponsor’s controlled process, and preserve clear sponsor decision authority.
Engagement options
BioBoston leads the defined scope from assessment and planning through drafting or execution, review, quality control, and handoff.
BioBoston addresses a specific section, decision, backlog, finding, vendor issue, or stalled deliverable without expanding the engagement unnecessarily.
BioBoston provides an objective second-line review, oversight role, or embedded specialist while the sponsor or another vendor retains primary execution.
RELATED SERVICES
Apply risk-based sponsor controls and retain evidence over delegated clinical activities.
Investigate and remediate deviations, findings, trends, or quality-system weaknesses identified through the framework.
Independently assess whether study, site, vendor, system, and process controls are implemented and effective.
Coordinate timelines, dependencies, decisions, vendors, issues, and escalation required to execute quality actions.
Expertise
Clinical quality-management experience should match the study phase, product and participant risk, protocol complexity, data and system model, vendor landscape, geography, and sponsor quality maturity.
RESOURCES
Explore the following resources for additional insights and information relevant to this service.
A planned template for critical-to-quality factors, risks, controls, indicators, thresholds, review, decisions, and escalation.
A planned guide to initial risk assessment, signal review, quality tolerance, issue management, governance, and adaptation.
A planned checklist for definitions, data sources, validation, thresholds, trends, ownership, actions, and retained evidence.
FAQs
They support the design and operation of study or program quality plans, risk-based quality management, critical-to-quality factors, quality signals, governance, issue escalation, and retained evidence.
No. Clinical quality management focuses on quality risk, controls, signals, governance, and improvement. Clinical trial and project management focus on operational delivery, milestones, resources, and coordination.
Yes. The plan should be study-specific and connect critical risks to controls, indicators, thresholds, data sources, owners, review cadence, actions, and escalation.
Quality tolerance or indicator support may be included when applicable and when the protocol, critical factors, data sources, methods, governance, and sponsor decisions are available.
Yes. A recurring role may facilitate signal review, trend assessment, dashboards, issue triage, governance preparation, decisions, and action follow-up within defined sponsor authority.
No. Risk-based quality management can improve focus, detection, decision making, and documentation,
but it does not eliminate sponsor responsibility or guarantee compliance or study outcomes.
PROJECT FORM
Share the study or program, quality framework, risk assessments, key signals, vendors, issue history, governance, and target milestone. A BioBoston team member will review the request and follow up regarding fit and possible next steps.
Please do not submit confidential, patient-identifiable, or proprietary information through this form.
A productive first discussion identifies the study, critical risks, existing plans, signals, vendors, governance, issues, and the next milestone. BioBoston can then define the assessment, framework, implementation, or recurring quality-governance role.
